The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 19, 2022

Filed:

Aug. 23, 2017
Applicant:

Dicerna Pharmaceuticals, Inc., Lexington, MA (US);

Inventors:

Weimin Wang, Newton, MA (US);

Venkata Krishnamurthy, Ashland, MA (US);

Assignee:

Dicerna Pharmaceuticals, Inc., Lexington, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); C07H 19/06 (2006.01); A61K 31/712 (2006.01); A61K 9/107 (2006.01); C07H 21/00 (2006.01); C12N 15/113 (2010.01);
U.S. Cl.
CPC ...
C07H 19/06 (2013.01); A61K 9/107 (2013.01); A61K 31/712 (2013.01); C07H 21/00 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12N 2310/11 (2013.01); C12N 2310/113 (2013.01); C12N 2310/12 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2310/20 (2017.05); C12N 2310/314 (2013.01);
Abstract

Disclosed herein are glutathione-sensitive oligonucleotides and methods of using the same. The glutathione-sensitive oligonucleotides may comprise at least one nucleotide represented by Formula I: wherein A, B, I, J, L, R, R, R, R, U, U, W, and X are as defined in the specification. An illustrative glutathione-sensitive oligonucleotide of the disclosure may have the following chemical structure: Any oligonucleotide of interest may be modified with a glutathione-sensitive moiety, including oligonucleotides used for in vivo delivery, such as nucleic acid inhibitor molecules. Also disclosed are glutathione-sensitive nucleotide and nucleoside monomers, including glutathione-sensitive nucleoside phosphoramidites that can be used, for example, in standard oligonucleotide synthesis methods. In addition, glutathione-sensitive nucleotide and nucleoside monomers without a phosphoramidite can be used therapeutically, for example, as anti-viral agents.


Find Patent Forward Citations

Loading…